Biomedical research at Oslo University Hospital
Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.
Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.
Click here to see hierarchical division and subunit overview
Summary of publications:
Publications (original articles or review articles) published in 2020 from OUS - Molecular Genetic Studies of Breast and Ovarian Cancer
25 publications found
Comparable cancer-relevant mutation profiles in synchronous ductal carcinoma in situ and invasive breast cancer
Cancer Rep (Hoboken), 3 (3), e1248
DOI 10.1002/cnr2.1248, PubMed 32671987
Contrasting DCIS and invasive breast cancer by subtype suggests basal-like DCIS as distinct lesions
NPJ Breast Cancer, 6, 26
DOI 10.1038/s41523-020-0167-x, PubMed 32577501
Epigenome-wide gene-age interaction analysis reveals reversed effects of PRODH DNA methylation on survival between young and elderly early-stage NSCLC patients
Aging (Albany NY), 12 (11), 10642-10662
DOI 10.18632/aging.103284, PubMed 32511103
MiR-18a and miR-18b are expressed in the stroma of oestrogen receptor alpha negative breast cancers
BMC Cancer, 20 (1), 377
DOI 10.1186/s12885-020-06857-7, PubMed 32370743
AXL Is a Driver of Stemness in Normal Mammary Gland and Breast Cancer
iScience, 23 (11), 101649
DOI 10.1016/j.isci.2020.101649, PubMed 33103086
A network analysis to identify mediators of germline-driven differences in breast cancer prognosis
Nat Commun, 11 (1), 312
DOI 10.1038/s41467-019-14100-6, PubMed 31949161
Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes
Nat Genet, 52 (1), 56-73
DOI 10.1038/s41588-019-0537-1, PubMed 31911677
Transcriptome-wide association study of breast cancer risk by estrogen-receptor status
Genet Epidemiol, 44 (5), 442-468
DOI 10.1002/gepi.22288, PubMed 32115800
Re-definition of claudin-low as a breast cancer phenotype
Nat Commun, 11 (1), 1787
DOI 10.1038/s41467-020-15574-5, PubMed 32286297
Modeling molecular development of breast cancer in canine mammary tumors
Genome Res (in press)
DOI 10.1101/gr.256388.119, PubMed 33361113
Molecular characterisation of TP53 mutated squamous cell carcinomas of the lung to identify putative targets for therapy
Int J Cancer, 147 (10), 2957-2966
DOI 10.1002/ijc.33121, PubMed 32468587
Radiological review of prior screening mammograms of screen-detected breast cancer
Eur Radiol
DOI 10.1007/s00330-020-07130-y, PubMed 33001307
The expression of the long NEAT1_2 isoform is associated with human epidermal growth factor receptor 2-positive breast cancers
Sci Rep, 10 (1), 1277
DOI 10.1038/s41598-020-57759-4, PubMed 31992741
Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk
Am J Hum Genet, 107 (5), 837-848
DOI 10.1016/j.ajhg.2020.09.001, PubMed 33022221
ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer
J Transl Med, 18 (1), 269
DOI 10.1186/s12967-020-02421-w, PubMed 32620163
Spatial transcriptomics inferred from pathology whole-slide images links tumor heterogeneity to survival in breast and lung cancer
Sci Rep, 10 (1), 18802
DOI 10.1038/s41598-020-75708-z, PubMed 33139755
Immune checkpoint blockade in the treatment of advanced non-small cell lung cancer - predictors of response and impact of previous radiotherapy
Acta Oncol, 60 (2), 149-156
DOI 10.1080/0284186X.2020.1854851, PubMed 33356733
DNA copy number motifs are strong and independent predictors of survival in breast cancer
Commun Biol, 3 (1), 153
DOI 10.1038/s42003-020-0884-6, PubMed 32242091
Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer - the MetAction study
Acta Oncol, 59 (7), 733-740
DOI 10.1080/0284186X.2020.1742377, PubMed 32208873
Secreted breast tumor interstitial fluid microRNAs and their target genes are associated with triple-negative breast cancer, tumor grade, and immune infiltration
Breast Cancer Res, 22 (1), 73
DOI 10.1186/s13058-020-01295-6, PubMed 32605588
Coagulation factor V is a marker of tumor-infiltrating immune cells in breast cancer
Oncoimmunology, 9 (1), 1824644
DOI 10.1080/2162402X.2020.1824644, PubMed 33457104
Immune phenotype of tumor microenvironment predicts response to bevacizumab in neoadjuvant treatment of ER-positive breast cancer
Int J Cancer, 147 (9), 2515-2525
DOI 10.1002/ijc.33108, PubMed 32488909
Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses
Nat Genet, 52 (6), 572-581
DOI 10.1038/s41588-020-0609-2, PubMed 32424353
Independent Validation of Early-Stage Non-Small Cell Lung Cancer Prognostic Scores Incorporating Epigenetic and Transcriptional Biomarkers With Gene-Gene Interactions and Main Effects
Chest, 158 (2), 808-819
DOI 10.1016/j.chest.2020.01.048, PubMed 32113923
Subtype-specific transcriptional regulators in breast tumors subjected to genetic and epigenetic alterations
Bioinformatics, 36 (4), 994-999
DOI 10.1093/bioinformatics/btz709, PubMed 31529022